Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis

'No evidence of disease activity' (NEDA), defined as absence of magnetic resonance imaging activity (T2 and/or gadolinium-enhanced T1 lesions), relapses and disability progression ('NEDA-3'), is used as a comprehensive measure of treatment response in relapsing multiple sclerosis...

Full description

Saved in:

Bibliographic Details
Published in:	Multiple sclerosis Vol. 22; no. 10; pp. 1297 - 1305
Main Authors:	Kappos, Ludwig, De Stefano, Nicola, Freedman, Mark S, Cree, Bruce Ac, Radue, Ernst-Wilhelm, Sprenger, Till, Sormani, Maria Pia, Smith, Terence, Häring, Dieter A, Piani Meier, Daniela, Tomic, Davorka
Format:	Journal Article
Language:	English
Published:	England 01.09.2016
Subjects:	Adolescent Adult Atrophy Brain - diagnostic imaging Brain - pathology Clinical Trials, Phase III as Topic Female Fingolimod Hydrochloride - therapeutic use Humans Immunosuppressive Agents - therapeutic use Magnetic Resonance Imaging Male Middle Aged Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging Multiple Sclerosis, Relapsing-Remitting - drug therapy Organ Size Treatment Outcome Young Adult Atrophy NEDA brain fingolimod multiple sclerosis
ISSN:	1477-0970
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!